Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) - Pipeline Review, H1 2016

  • ID: 3788894
  • Report
  • 58 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Neurimmune Holding AG
  • ProMIS Neurosciences Inc.
  • MORE
Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) - Pipeline Review, H1 2016

Summary

‘Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) - Pipeline Review, H1 2016’, provides in depth analysis on Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1)
- The report reviews Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Neurimmune Holding AG
  • ProMIS Neurosciences Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) Overview

Therapeutics Development

Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) - Products under Development by Stage of Development

Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) - Products under Development by Therapy Area

Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) - Products under Development by Indication

Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) - Products under Development by Companies

Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) - Products under Development by Universities/Institutes

Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) - Companies Involved in Therapeutics Development

Ionis Pharmaceuticals, Inc.

Neurimmune Holding AG

ProMIS Neurosciences Inc.

RXi Pharmaceuticals Corporation

Voyager Therapeutics, Inc.

Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) - Drug Profiles

ISIS-SOD1Rx - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit Superoxide Dismutase 1 for Amyotrophic Lateral Sclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit SOD1 for Amyotropic Lateral Sclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NI-204 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RNAi Gene Therapy to Inhibit SOD1 for Amyotrophic Lateral Sclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RNAi Oligonucleotide to Inhibit SOD-1 for ALS - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate SOD-1 for Amyotrophic Lateral Sclerosis and Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Superoxide Dismutase 1 for Amyotrophic Lateral Sclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TDI-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tetrathiomolybdate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VYSOD-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WTX-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) - Dormant Projects

Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) - Featured News & Press Releases

May 30, 2016: Wilson Therapeutics Presents Encouraging Clinical Data On Decuprate At The Congress Of The European Academy Of Neurology

May 18, 2016: Wilson Therapeutics Announces That the Ongoing Phase II Study Has Been Fully Enrolled

Apr 29, 2016: Voyager Therapeutics Highlights Program in ALS Disease

Apr 14, 2016: Wilson Therapeutics presents data on Decuprate™ (WTX101) from ongoing Phase 2 study at The International Liver Congress™ 2016

Dec 11, 2015: Isis Pharmaceuticals Announces Initiation of Phase 1/2 Clinical Study of ISIS-SOD1 Rx in Patients With ALS

Apr 16, 2015: Wilson Therapeutics Announces Presentation Of WTX101-201 Phase 2 Study At The EASL 50th International Liver Congress 2015

Nov 17, 2014: Wilson Therapeutics Announces Start Of Phase 2 Study To Evaluate The Efficacy And Safety Of WTX101 In Newly Diagnosed Wilson Disease Patients

Jan 13, 2014: Wilson Therapeutics Announces Successful Filing of U.S. IND to Advance WTX101 Development Program for Wilson Disease

Apr 03, 2013: MGH And Washington University Researchers Announce Isis Pharma's SOD1 Antisense Drug Demonstrates Safety In Phase I ALS Trial

Feb 13, 2013: Copper Depletion Therapy May Prevent Risk Of Triple-Negative Breast Cancer, Study Finds

Apr 28, 2011: RXi Pharmaceuticals and the University of Massachusetts Medical School Announce Massachusetts Life Sciences Center Cooperative Research Grant for RNAi Therapeutics for ALS

Mar 08, 2010: ISIS Initiates Phase I Clinical Trial Of ISIS-SOD1Rx In Patients With Amyotrophic Lateral Sclerosis

Dec 13, 2007: Isis Pharmaceuticals Announces ISIS 333611 Granted Orphan Drug Status For Treatment Of ALS

May 24, 2004: Attenuon Announces Launch Of ATN-224 Phase I Trial In Patients With Solid Tumors

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 58List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Ionis Pharmaceuticals, Inc., H1 2016

Pipeline by Neurimmune Holding AG, H1 2016

Pipeline by ProMIS Neurosciences Inc., H1 2016

Pipeline by RXi Pharmaceuticals Corporation, H1 2016

Pipeline by Voyager Therapeutics, Inc., H1 2016

Dormant Projects, H1 2016 45List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Neurimmune Holding AG
  • ProMIS Neurosciences Inc.
  • MORE
Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) pipeline Target constitutes close to 12 molecules. Out of which approximately 7 molecules are developed by Companies and remaining by the Universities/Institutes. Our latest report Superoxide Dismutase [Cu-Zn] – Pipeline Review, H1 2016, outlays comprehensive information on the Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) Superoxide dismutase (SOD) is an enzyme that alternately catalyzes the dismutation of the superoxide (O2-) radical into either ordinary molecular oxygen (O2) or hydrogen peroxide (H2O2) which prevents damage to tissues. Superoxide dismutase is used for treating pain and swelling (inflammation) caused by osteoarthritis, sports injuries, and rheumatoid arthritis, a kidney condition called interstitial cystitis, gout, poisoning caused by a weed-killer called paraquat, cancer, and lung problems in newborns. The molecules developed by Companies in Phase II and Preclinical stages are 2 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively.

Furthermore, this report also reviews key players involved in Superoxide Dismutase [Cu-Zn](Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or EC 1.15.1.1) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Ionis Pharmaceuticals, Inc.
Neurimmune Holding AG
ProMIS Neurosciences Inc.
RXi Pharmaceuticals Corporation
Voyager Therapeutics, Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll